2225819-06-5

Usage

Uses

Used in Pharmaceutical Industry:
N-(2-chloro-6-fluorophenyl)-4-[4-ethyl-3-(hydroxymethyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-5-fluoro-2-[(2S)-1,1,1-trifluoropropan-2-yl]oxybenzamide is used as a pharmaceutical compound for its potential therapeutic properties. Its unique structure may allow it to interact with specific biological targets, offering new avenues for the treatment of various diseases.
Used in Research Applications:
In the field of research, N-(2-chloro-6-fluorophenyl)-4-[4-ethyl-3-(hydroxymethyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-5-fluoro-2-[(2S)-1,1,1-trifluoropropan-2-yl]oxybenzamide serves as a valuable chemical entity for studying its interactions with biological systems. Its diverse functional groups and structural features make it an interesting subject for exploring new mechanisms of action and potential applications in drug discovery and development.

Upstream product

• 363-51-9 2-chloro-6-fluoroaniline 
• 133541-45-4 4-bromo-2,5-difluoro-benzonitrile 

Relevant academic research and scientific papers

METHOD FOR THE PREPARATION OF A 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONE

The present invention provides methods for the preparation of Compound (I): Compound (I), the use of intermediates for the preparation of said compound and its crystalline form A.

METHODS OF TREATMENT WITH A 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONE

The present invention provides a method of treating a mutant IDH cancer in a subject comprising administering to a subject in need thereof a therapeutically effective amount of Compound (I): and the use of said compound for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders bearing an IDH mutation, as a sole agent or in combination with other active ingredients.

COMBINATIONS OF COPANLISIB WITH TRIAZOLONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER

The present invention relates to : * combinations of : component A : one or more 2,3-dihydroimidazo[l,2-c]quinazoline compounds of general formula (Al) or (A2) as defined herein, or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof; component B : one or more dihydroorotate dehydrogenase (DHODH)-inhibiting 2,4,5- trisubstituted 1,2,4-triazolone compounds of general formula (B-l) as defined herein, or a tautomer, an N-oxide, a salt, a salt of a tautomer or a salt of an N-oxide thereof; in which optionally some or all of the components are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially. dependently of one another by the oral, intravenous, topical, local installations, intraperitoneal or nasal route; * use of such combinations for the preparation of a medicament for the treatment or prophylaxis of a cancer; and * a kit comprising such a combination.

5-OXO-4,5-DIHYDRO-1H-1,2,4-TRIAZOL DERIVATIVES FOR THE TREATMENT OF CANCER

The present invention provides Compound (I), 2-butoxy-N-(2-chloro-6-fluorophenyl)-4-[3-(2-chlorophenyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-5-fluorobenzamide and Compound (II), N-(2-chloro-6-fluorophenyl)-4-[4-ethyl-3-(hydroxymethyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-5-fluoro-2-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy}benzamide, (II): and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same, methods for the preparation of Compound (I) and Compound (II) and their use for the treatment of hyperproliferative diseases, particularly cancer.

2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH

The present invention provides triazolone compounds compounds of general formula (I) : in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.